Where does the Potential Lie for Players in Whole Genome Sequencing?
As per the new research report by RNCOS, “US Personalized Cancer Genome Sequencing Market”, a huge potential market lays untapped for the players in the whole genome sequencing (WGS) business. Buoyed by the positive opinion created from media stories about the various successful personalized cancer therapies that were aided by WGS, a lot of Americans suffering from cancer are interested in availing the services, despite the high costs. Most of these costs involve the fees of experts, oncologists and are not covered by insurance. Still, around 881,667 US citizens stand as potential customers, willing to pay out-of-pocket for personalized cancer WGS services.
